Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NICE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NICE and 80,000+ other tickers.
See exactly how NICE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NICE and 80,000+ other tickers.
NICE Ltd., together with its subsidiaries, provides AI-powered cloud platforms for customer engagement, and financial crime and compliance in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Customer Engagement; and Financial Crime and Compliance. The Customer Engagement segment provides CXone Mpower platform for organizations to automate service, augment the workforce with AI-powered solutions, and unify enterprise knowledge, data and AI models resolutions, and customer experiences. The Financial Crime and Compliance segment offers…
The latest trading day saw Nice (NICE) settling at $101.34, representing a +1.19% change from its previous close.
Nice (NICE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Enables natural orifice extraction of tissue without surgical incision SINGAPORE, July 20, 2026 /PRNewswire/ -- NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments, has been granted U.S. Patent No. 12,661,097 B2, for its extracting device used in conjunction with its novel purse-string stapler, generally eliminating the need for surgical incisions in colorectal surgery.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
NICE provides highly profitable AI-driven customer engagement solutions and financial crime compliance software. Twilio offers a massive programmable communications platform that powers messaging and data for over 402,000 active accounts.